Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5749934 | 0.86 | TDP1 (0.72) | TDP1ALDH1A1RAB9AGAAMAPK8 | |
| SCHEMBL5745815 | 0.85 | TDP1 (0.52) | TDP1ALDH1A1RAB9APDE10AGAA | |
| SCHEMBL6457226 | 0.84 | TDP1 (0.64) | TDP1ALDH1A1RAB9APDE10AGAA | |
| SCHEMBL2781160 | 0.84 | GAA (0.67) | TDP1ALDH1A1RAB9APDE10AGAA | |
| SCHEMBL861902 | 0.83 | TDP1 (0.71) | TDP1ALDH1A1RAB9APDE10AGAA | |
| SCHEMBL11810048 | 0.82 | PDE10A (0.60) | TDP1ALDH1A1RAB9APDE10AGAA | |
| SCHEMBL8730078 | 0.81 | TDP1 (0.65) | TDP1ALDH1A1RAB9APDE10AGAA | |
| SCHEMBL11814538 | 0.81 | TDP1 (0.57) | TDP1ALDH1A1RAB9APDE10AGAA | |
| SCHEMBL2779334 | 0.81 | RAB9A (0.76) | TDP1ALDH1A1RAB9APDE10AGAA | |
| SCHEMBL2779361 | 0.81 | KMT2A (0.65) | TDP1ALDH1A1RAB9APDE10AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141586-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1651609-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2005009966-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009966-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | CBR3, CBR1, PDE9A | TDP1 1674/4885ALDH1A1 1353/4885RAB9A 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.